Cache challenge 6 update

ANYO Labs Advances to Stage 2 of the CACHE 6 Challenge: Pioneering AI-Driven Hit Discovery

ANYO Labs advances to the final stage of the CACHE 6 Challenge, where we achieved the highest number of validated hits identified—positioning us among the select few companies to progress. This milestone underscores the power of our iScore AI platform in tackling one of drug discovery's toughest problems: finding ligands for challenging protein domains.

The CACHE (Critical Assessment of Computational Hit-Finding Experiments) initiative is a landmark community effort to benchmark computational tools against real-world biology. Launched by the Structural Bioinformatics community, it provides an open, independent platform for evaluating AI and virtual screening methods.

Challenge 6 specifically targets the triple Tudor domain of SETDB1, a histone methyltransferase implicated in epigenetic regulation and cancer progression. Identifying high-affinity ligands here is vital—SETDB1's role in silencing tumor suppressors contributes to aggressive cancers like melanoma and glioblastoma, where current therapies fall short. Success in this challenge could unlock new epigenetic therapies, reducing development costs and accelerating precision medicine.

This third-party validation not only builds credibility but also refines our algorithms, ensuring even greater reliability for partners.

50 analogues based on all our discovered compounds will advance to the final round early 2026, with all structures to be publicly disclosed thereafter. We're excited to contribute to CACHE's mission and invite collaborations to harness this innovation for transformative therapies.